Common Stock, par value $0.001 per share
- Symbol
- QNCX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Historical · closed Oct 9, 2026
Current Report · Items 2.02, 9.01 · 8-K
IRulya Therapeutics Inc.
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On August 14, 2026, Quince Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026 and provided recent business highlights. A copy of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.…
Press release in this filing
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update →Company context
Quince Therapeutics, Inc. is committed to transforming the lives of patients facing serious, underserved diseases by developing disease-modifying therapies to treat their conditions. The company is currently developing LAM-001 for the treatment of PH-ILD, BOS, and SAPH. A Phase 2a study in PH patients has been completed, a Phase 2 clinical study in BOS patients is ongoing, a Phase 2b study in PH-ILD is ongoing, and a Phase 2 study in SAPH is anticipated to begin in late 2026. By pioneering innovative approaches, the company aims to offer new hope and improved quality of life to patients worldwide.
Current securities
Historical securities (1)
Registered securities in this filing
QUINCE THERAPEUTICS, INC. · 8-K · Filed 2026-08-14
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition
On August 14, 2026, Quince Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026 and provided recent business highlights. A copy of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such filing.
Filed exhibits (1)
EX-99.1 2 d163839dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline LAM-001 Phase 2b data in PH-ILD anticipated in the first quarter of 2028; Phase 2 data in BOS anticipated in the first quarter of 2027 Closed private placement financing, receiving $115 million in upfront gross proceeds, with potential for up to an additional $83 million upon exercise of warrants (including warrants issued to former Orphai stockholders) Cash and cash equivalents of $116 million as of June 30, 2026, expected to fund operations through the end of 2028 South San Francisco, CA, August 14, 2026 - Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2026. “This was a transformational quarter for the company with…
Open exhibit ↗